

BioWorld®

---

BIOTECHNOLOGY

---

STATE OF THE

---

INDUSTRY

---

REPORT

---

2 0 1 1

---

<b>Analysis</b>	<b>11</b>
Biotech 'Just Deals With It' in 2010	13
Biotech's IPO Rally Counters Tough Markets, R&D Setbacks	18
Uncertainty Clouds Health Care Reform, FDA Approval Process	20
Investments Rebounded, But European Biotechs Still Underfunded	23
The Light Bulb Burns Bright in the Discovery Phase	26
<b>Financial Data</b>	<b>29</b>
<b>Corporate Deals</b>	<b>115</b>
2010 Biotech M&As and Collaborations: 'No Big Deal'	117
<b>Biotech Product Development</b>	<b>241</b>
<b>Report Card For Wall Street</b>	<b>299</b>
<b>Stock Performance</b>	<b>311</b>
<b>Restructurings</b>	<b>317</b>
<b>Lawsuits</b>	<b>325</b>



<b>Analysis</b>	<b>11</b>
Revenue of the Market-Leading Biotech Drugs in 2010	14
Revenue of the Top Biotech Drugs, 2003-2010	17
<b>Financial Data</b>	<b>29</b>
Biotech Money Raised By Month In 2010: Jan. - Dec.	31
Initial Public Offerings Of Biotechnology In 2010	32
Biotechnology Follow-On Offerings In 2010	35
2010 Initial Public Offerings	44
2010 Follow-on Offerings	44
Gross Proceeds of Biotech Public Stock Offerings	45
Biotech Money Raised: 1997-2010	46
Nasdaq Stock Index	47
BioWorld Stock Index 2010	47
Other Financings Of Public Biotech Companies In 2010	49
Venture Capital And Other Investments In Private	76
Biotechnology Companies In 2010	76
Milestone Payments From Corporate Partners in 2010	94
Grants and Awards Given to Biotech Companies in 2010	101
<b>Corporate Deals</b>	<b>115</b>
2010-2009 M&As	117
2009-2010 Biotech-Pharma Collaborations	117
2009-2010 Biotech-Biotech Collaborations	117
2010 Top 10 M&As	118
2010 Top 10 Biotech-Pharma Collaborations	119
2010 Top 10 Biotech-Biotech Collaborations	121
Biotech Mergers And Acquisitions In 2010	123
Biotechnology Company Deals With Pharmaceutical Companies In 2010	131
Modified Deals Between Biotechs and Pharmas in 2010	159
Terminated Deals Between Biotechs and Pharmas in 2010	167
Manufacturing/Supply/Distribution Deals Between Biotechs and Pharmas in 2010	170
Biotechnology Company Deals With Other Biotechnology Companies In 2010	179
Biotech-Biotech Collaborations: Modified Agreements for 2010	205
Biotech-Biotech Collaborations: Terminated Agreements in 2010	209
Manufacturing, Marketing And Distribution Agreements Between Biotech Companies in 2010	211
Collaborations Between Biotechnology Companies And Government/Nonprofit Institutions In 2010	216
<b>Biotech Product Development</b>	<b>241</b>
Biotechnology Products Approved by the FDA in 2010	243
Biotech Products: 1982-2010, A-Z	249
FDA Actions on Pending Applications in 2010	273
Licensing Applications Filed and Pending at FDA in 2010	277
Recommendations by FDA Advisory Panels in 2010	282
Overseas Approvals and Other Regulatory Actions in 2010	285
Orphan Designations Granted in 2010	292

<b>Report Card For Wall Street</b>	<b>299</b>
U.S. Public Offering Performance By Underwriter: Jan. 1 - Dec. 31, 2010	301
U.S. Public Offering Performance By Underwriter: Jan. 1 - Dec. 31, 2010	303
Lead Underwriter Performance on All U.S. Offerings: Jan. 1 - Dec. 31, 2010	305
Lead Underwriter Performance on All U.S. Offerings: Jan. 1 - Dec. 31, 2010	306
Underwriters' Performance on IPOs: Jan. 1 - Dec. 31, 2010	307
Underwriters' Performance on IPOs: Jan. 1 - Dec. 31, 2010	308
Underwriters' Performance on IPOs: Jan. 1 - Dec. 31, 2010	309
<b>Stock Performance</b>	<b>311</b>
2010 U.S. Biotechnology Stock Report	313
2010 British Biotechnology Stock Report	315
2010 Canadian Biotechnology Stock Report	316
<b>Restructurings</b>	<b>317</b>
Biotech Restructurings, Scale-Backs, Bankruptcies	319
<b>Lawsuits</b>	<b>325</b>
Biotech Lawsuits: Jan. 1 - Dec. 31, 2010	327